炎症性肠病新型生物制剂的研发进展
Advances in the development of new biologics in inflammatory bowel disease.
作者信息
Ungar Bella, Kopylov Uri
机构信息
Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, and Sackler Faculty of Medicine, Tel Aviv University, Israel.
出版信息
Ann Gastroenterol. 2016 Jul-Sep;29(3):243-8. doi: 10.20524/aog.2016.0027. Epub 2016 Mar 24.
Abstract
Biologics have revolutionized the therapeutic approach in inflammatory bowel disease (IBD). Anti-tumor necrosis factor (anti-TNF) agents infliximab and adalimumab currently constitute the major biological therapy in IBD. Additional anti-TNFs such as golimumab and other new biologics are currently being developed for both anti-TNF-naïve and -resistant patients. These include anti-integrins (vedolizumab and etrolizumab), a JAK inhibitor (tofacitinib) and an anti-anti-interleukin (IL)-23 and IL-12 antibody (ustekinumab), among additional drugs in development. The following review discusses the indications, efficacy and safety issues for these novel medications.
摘要
生物制剂彻底改变了炎症性肠病（IBD）的治疗方法。抗肿瘤坏死因子（抗TNF）药物英夫利昔单抗和阿达木单抗目前构成了IBD的主要生物治疗方法。目前正在为未使用过抗TNF药物和对抗TNF药物耐药的患者研发其他抗TNF药物，如戈利木单抗以及其他新型生物制剂。这些药物包括抗整合素（维多珠单抗和依曲珠单抗）、一种JAK抑制剂（托法替布）和一种抗白细胞介素（IL）-23和IL-12抗体（乌司奴单抗），以及其他正在研发的药物。以下综述讨论了这些新型药物的适应症、疗效和安全性问题。
相似文献
1
Advances in the development of new biologics in inflammatory bowel disease.炎症性肠病新型生物制剂的研发进展
Ann Gastroenterol. 2016 Jul-Sep;29(3):243-8. doi: 10.20524/aog.2016.0027. Epub 2016 Mar 24.
2
Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives.生物制剂和生物类似药在炎症性肠病中的作用：当前趋势与未来展望
J Inflamm Res. 2018 May 16;11:215-226. doi: 10.2147/JIR.S165330. eCollection 2018.
4
Biologics in inflammatory bowel disease: what are the data?炎症性肠病中的生物制剂：有哪些数据？
United European Gastroenterol J. 2015 Oct;3(5):419-28. doi: 10.1177/2050640615590302.
5
Biologic drugs for inflammatory bowel disease.用于炎症性肠病的生物药物。
Nihon Rinsho. 2017 Mar;75(3):403-407.
6
Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.目前、新出现的以及即将出现的用于治疗炎症性肠病的生物制剂。
Therap Adv Gastroenterol. 2015 Mar;8(2):66-82. doi: 10.1177/1756283X14558193.
7
Emerging biologics in inflammatory bowel disease.炎症性肠病中的新兴生物制剂。
J Gastroenterol. 2017 Feb;52(2):141-150. doi: 10.1007/s00535-016-1283-0. Epub 2016 Nov 10.
8
A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.抗 TNF 在儿童和青少年炎症性肠病中的应用综述
Int J Mol Sci. 2019 May 23;20(10):2529. doi: 10.3390/ijms20102529.
9
Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.英夫利昔单抗和乌司奴单抗治疗肿瘤坏死因子-α拮抗剂治疗失败后克罗恩病的成本效益分析
Pharmacoeconomics. 2018 Jul;36(7):853-865. doi: 10.1007/s40273-018-0653-2.
10
Next-Generation Therapeutics for IBD.炎症性肠病的新一代疗法
Curr Gastroenterol Rep. 2015 Jun;17(6):21. doi: 10.1007/s11894-015-0444-2.
引用本文的文献
1
Efficacy and safety of etrolizumab in the treatment of inflammatory bowel disease: a meta-analysis.依特利珠单抗治疗炎症性肠病的疗效和安全性：一项荟萃分析。
PeerJ. 2024 Aug 23;12:e17945. doi: 10.7717/peerj.17945. eCollection 2024.
2
Development of an Inflammation-Triggered In Vitro "Leaky Gut" Model Using Caco-2/HT29-MTX-E12 Combined with Macrophage-like THP-1 Cells or Primary Human-Derived Macrophages.利用 Caco-2/HT29-MTX-E12 联合巨噬细胞样 THP-1 细胞或原代人源巨噬细胞建立炎症触发的体外“肠漏”模型。
Int J Mol Sci. 2023 Apr 18;24(8):7427. doi: 10.3390/ijms24087427.
3
Acteoside alleviates dextran sulphate sodium‑induced ulcerative colitis via regulation of the HO‑1/HMGB1 signaling pathway.毛蕊花糖苷通过调控 HO-1/HMGB1 信号通路缓解葡聚糖硫酸钠诱导的溃疡性结肠炎。
Mol Med Rep. 2022 Dec;26(6). doi: 10.3892/mmr.2022.12877. Epub 2022 Oct 25.
4
Inflammation Modulating Activity of the Hydroethanol Stem Bark Extract of in Murine Models.[植物名称]水乙醇茎皮提取物在小鼠模型中的炎症调节活性
Scientifica (Cairo). 2022 Aug 22;2022:6882147. doi: 10.1155/2022/6882147. eCollection 2022.
5
Interaction Between Commensal Bacteria, Immune Response and the Intestinal Barrier in Inflammatory Bowel Disease.炎症性肠病中共生菌、免疫应答与肠道屏障的相互作用
Front Immunol. 2021 Nov 11;12:761981. doi: 10.3389/fimmu.2021.761981. eCollection 2021.
6
Endocannabinoid Levels in Ulcerative Colitis Patients Correlate With Clinical Parameters and Are Affected by Cannabis Consumption.溃疡性结肠炎患者的内源性大麻素水平与临床参数相关，并受大麻使用的影响。
Front Endocrinol (Lausanne). 2021 Aug 31;12:685289. doi: 10.3389/fendo.2021.685289. eCollection 2021.
7
Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial.大麻与溃疡性结肠炎的临床缓解而非内镜缓解相关：一项随机对照试验。
PLoS One. 2021 Feb 11;16(2):e0246871. doi: 10.1371/journal.pone.0246871. eCollection 2021.
8
Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries.用于炎症性肠病管理的生物制剂：在结核病流行国家的综述。
Gut Liver. 2020 Nov 15;14(6):685-698. doi: 10.5009/gnl19209.
9
Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study.在GEMINI 1研究中维多珠单抗治疗亚洲国家溃疡性结肠炎患者的疗效与安全性。
Intest Res. 2021 Jan;19(1):71-82. doi: 10.5217/ir.2019.09159. Epub 2020 Sep 4.
10
Role of NLRP3 inflammasome in inflammatory bowel diseases.NLRP3 炎性小体在炎症性肠病中的作用。
World J Gastroenterol. 2019 Sep 7;25(33):4796-4804. doi: 10.3748/wjg.v25.i33.4796.
本文引用的文献
1
Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.维多珠单抗在炎症性肠病临床实践中使用第一年的有效性和安全性。
J Crohns Colitis. 2016 Apr;10(4):402-9. doi: 10.1093/ecco-jcc/jjv226. Epub 2015 Dec 17.
2
Promising biological therapies for ulcerative colitis: A review of the literature.溃疡性结肠炎有前景的生物疗法：文献综述
World J Gastrointest Pathophysiol. 2015 Nov 15;6(4):219-27. doi: 10.4291/wjgp.v6.i4.219.
3
New pharmaceuticals in inflammatory bowel disease.炎症性肠病的新型药物
Prz Gastroenterol. 2015;10(2):57-60. doi: 10.5114/pg.2015.52702. Epub 2015 Jul 1.
4
Biologics in inflammatory bowel disease: what are the data?炎症性肠病中的生物制剂：有哪些数据？
United European Gastroenterol J. 2015 Oct;3(5):419-28. doi: 10.1177/2050640615590302.
5
Immunogenicity, drug trough levels and therapeutic response in patients with rheumatoid arthritis or ankylosing spondylitis after 24-week golimumab treatment.类风湿关节炎或强直性脊柱炎患者接受戈利木单抗治疗24周后的免疫原性、药物谷浓度及治疗反应
Ann Rheum Dis. 2015 Dec;74(12):2261-4. doi: 10.1136/annrheumdis-2015-207978. Epub 2015 Oct 6.
6
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.皮下注射乌司奴单抗可为三分之二对肿瘤坏死因子拮抗剂治疗抵抗的克罗恩病患者带来临床获益。
Clin Gastroenterol Hepatol. 2016 Feb;14(2):242-50.e1-2. doi: 10.1016/j.cgh.2015.09.018. Epub 2015 Sep 30.
7
Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease.维得利珠单抗：一种用于溃疡性结肠炎和克罗恩病的 α4β7 整合素拮抗剂。
Ther Adv Chronic Dis. 2015 Sep;6(5):224-33. doi: 10.1177/2040622315586970.
8
Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort.维多珠单抗作为难治性炎症性肠病患者诱导治疗的疗效：一项多中心队列研究
Inflamm Bowel Dis. 2015 Dec;21(12):2879-85. doi: 10.1097/MIB.0000000000000561.
9
Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.随机临床试验：一项关于静脉注射戈利木单抗诱导治疗溃疡性结肠炎的安慰剂对照研究。
Aliment Pharmacol Ther. 2015 Sep;42(5):504-14. doi: 10.1111/apt.13291. Epub 2015 Jun 29.
10
Next-Generation Therapeutics for IBD.炎症性肠病的新一代疗法
Curr Gastroenterol Rep. 2015 Jun;17(6):21. doi: 10.1007/s11894-015-0444-2.
Zotero 插件